Clinical Trial Update: Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation [Phase 2]

View source ↗

Summary

Phase 2 trial investigating the long-term safety and efficacy of leniolisib in primary immunodeficiencies linked to PI3K is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Activated Pi3kδ Syndrome

Drugs mentioned

• Leniolisib (leniolisib)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: PIDs Linked to PI3K | Phase 2 | Status: RECRUITING